The Analytical Blueprint for Cell & Gene Therapy Success

Cell and gene therapies have transitioned into a more mature phase, with scientific advancements occurring rapidly. However, analytical and regulatory expectations have also intensified, determining whether groundbreaking treatments reach patients. In 2026, the regulatory environment has continued to evolve. The FDA implemented new CMC flexibilities tailored for cell and gene therapies, acknowledging that conventional development methods may not suit these intricate products.

Meanwhile, newly released Complete Response Letters (CRLs) have consistently offered insightful data regarding the analytical issues most often delaying approvals, while forthcoming ICH guidance and USP chapters are shaping expectations for extractables and leachables. These advancements underscore the increasing significance of analytical science.

Analytics has emerged as a strategic discipline, contributing to product comprehension, guiding manufacturing decisions, informing risk evaluations, and fostering confidence throughout the product lifecycle. Developers need to establish an integrated analytical strategy that adapts with the product, linking characterization, potency, safety, manufacturing, and regulatory requirements into a holistic understanding of quality.

This eBook compiles perspectives from experts on several crucial analytical subjects currently confronting cell and gene therapy developers. Within its pages, readers will discover how integrated analytics can prevent program deviations, how next-generation sequencing is revolutionizing product characterization and viral safety, why extractables and leachables necessitate novel approaches for cell and gene therapy products (CGTs), what FDA Complete Response Letters reveal about potency assays, and how recent FDA CMC flexibilities can expedite development.

Each article, while focusing on a distinct aspect of development, emphasizes a common theme: well-thought-out analytical strategies minimize uncertainty, enhance regulatory preparedness, and ultimately facilitate the transition of innovative therapies from the laboratory to patients in need.